Key result
Injection of the lipasin monoclonal antibody AB-2 reduced serum triglyceride levels by approximately 30% in mice at the fed state by increasing postprandial cardiac lipoprotein lipase activity.
Why the study?
Does a monoclonal lipasin antibody lower serum triglycerides and alter cardiac lipoprotein lipase activity in mice?
Population
Male wild-type and lipasin knockout (B6;129S5-Gm6484tm1Lex/Mmucd) mice, 6-8 weeks old.
Comparison
Monoclonal lipasin antibody 30 mg/kg i.p. daily… vs Control IgG from non-immunized mice, wild-type…
Design
Preclinical
Follow-up
up to 14 days
Authors
Loading...
Monoclonal lipasin antibody lowers TAG in mice; hypothesis-generating for LPL-targeted cardiometabolic therapies pending human data.
Does a monoclonal lipasin antibody lower serum triglycerides and alter cardiac lipoprotein lipase activity in mice?
Effect estimate: 30% decrease
Absolute Event Rate: 76% vs 110%
p-value: p=<0.05
Lipasin acts as an endocrine factor that inhibits LPL activity in cardiac and skeletal muscles during feeding, and its neutralization with a monoclonal antibody effectively lowers serum triglycerides in mice.
Fu et al. (2015) studied Normal physiology and triglyceride metabolism. Lipasin monoclonal antibody (AB-2) vs. Control IgG was evaluated on Serum triglyceride levels on day 3 (30% decrease, p=<0.05). Injection of the lipasin monoclonal antibody AB-2 reduced serum triglyceride levels by approximately 30% in mice at the fed state by increasing postprandial cardiac lipoprotein lipase activity.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: